Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as TPM XR
TPM · 1 trial · 1 indication
Relating to repeated oral dosing
| Arm | Type | Description |
|---|---|---|
| Conversion-25 | EXPERIMENTAL | 25 mg |
| Conversion-50 | EXPERIMENTAL | 50 mg |
| Conversion-100 | EXPERIMENTAL | 100 mg |
| Conversion-200 | EXPERIMENTAL | 200 mg |
| Name | Type | Description |
|---|---|---|
| TPM XR | DRUG | Equivalent TDD in XR form, QD, Day 1-14 |
Inclusion Criteria: 1. Able to provide written IAF, as appropriate, with written informed permission (including ICF where required by regional laws or regulations) from the parent or LAR. 2. Male or female aged 4 to 17 years, inclusive, with a current diagnosis of partial onset or primary generaliz...
Top 9 of 13 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Xenon Pharmaceuticals Inc. | XENE | 4 | PHASE3 | Azetukalner |
| Praxis Precision Medicines, Inc. | PRAX | 5 | PHASE3 | Vormatrigine, Elsunersen |
| Rapport Therapeutics, Inc. | RAPP | 3 | PHASE3 | RAP-219 |
| Supernus Pharmaceuticals, Inc. | SUPN | 4 | PHASE2 | SPN-817, Treatment B, BIS-001ER |
| Biohaven Ltd. | BHVN | 3 | PHASE2 | BHV-7000 |
| Harmony Biosciences Holdings, Inc. | HRMY | 1 | PHASE3 | Clemizole |
| Jazz Pharmaceuticals Public Limited Company | JAZZ | 3 | PHASE1 | CBD-OS, Epidiolex |
| Bright Minds Biosciences Inc. | DRUG | 1 | PHASE2 | BMB-101 |
| uniQure N.V. | QURE | 1 | PHASE1 | AMT-260 |
TPM is being studied as an adjunctive therapy for epilepsy, meaning it is added to existing seizure treatment rather than used alone. The clinical work on record is in pediatric patients with epilepsy, ages 4 years and older, in the United States. It is an investigational small molecule and is not established as an approved treatment.
TPM is being developed by Supernus Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker SUPN. The company is the sponsor behind the clinical program evaluating TPM XR as adjunctive therapy in pediatric epilepsy.
TPM is in Phase 1 clinical development. Its single recorded trial is a Phase 1 study, and no later-phase trials are on record. Because the program remains at this early stage, TPM is investigational and has not been shown to be approved for any indication.
TPM has been studied in one clinical trial, NCT01284530, titled Evaluation of the Pharmacokinetics, Safety, and Tolerability of TPM XR as Adjunctive Therapy in Pediatric Subjects With Epilepsy. That Phase 1 trial enrolled 30 participants in the United States, used a controlled and randomized design, and is now completed.
Yes, TPM XR is an alternative name for TPM. The two names refer to the same Supernus Pharmaceuticals asset, and the completed Phase 1 pediatric epilepsy trial is listed under the TPM XR name. Readers searching either term are looking at the same investigational program.
TPM XR is being evaluated as adjunctive therapy in pediatric patients with epilepsy, added alongside their existing antiseizure treatment. The completed Phase 1 trial assessed pharmacokinetics, safety, and tolerability in 30 participants aged 4 years and older. It is an investigational small molecule and is not an established epilepsy treatment.